3D Nanoporous Anodic Alumina Structures for Sustained Drug Release
Maria Porta-I-Batalla1, Elisabet Xifré-Pérez2, Chris Eckstein3
1Departament d'Enginyeria Electrònica, Elèctrica i Automàtica, ETSE, Universitat Rovira i Virgili, Avda. Països Catalans 26, 43007 Tarragona, Spain. maria.porta@urv.cat.
Nanomaterials (Basel, Switzerland)
|August 22, 2017
Summary
This study explores nanoporous anodic alumina (NAA) for drug delivery. Tailored 3D pore structures enable sustained drug release exceeding 60 days, optimizing delivery systems without initial bursts.
Area of Science:
- Materials Science
- Nanotechnology
- Biomedical Engineering
Background:
- Nanoporous anodic alumina (NAA) is a promising material for drug delivery systems.
- Drug release from NAA is significantly influenced by its pore morphology.
- Controlling drug release kinetics is crucial for effective therapeutic outcomes.
Purpose of the Study:
- To fabricate NAA with diverse 3D pore structures.
- To investigate and model the drug release rates from these structures.
- To demonstrate sustained drug release capabilities of engineered NAA.
Main Methods:
- Fabrication of NAA with cylindrical, nanofunnel, and inverted funnel pore geometries.
- Loading doxorubicin as a model drug into the NAA pores.
- Experimental study and mathematical modeling of drug release kinetics.
Main Results:
- Successful fabrication of NAA with distinct 3D pore architectures.
- Identification of two distinct drug release phases: short-term and long-term.
- Optimal modeling of drug release using Higuchi and Korsmeyer-Peppas equations.
Conclusions:
- Pore geometry critically influences drug release rates from NAA.
- Achieved sustained drug release over 60 days with minimal initial burst.
- Engineered NAA offers potential for advanced, controlled drug delivery applications.
Related Concept Videos
01:11Oral Drug Delivery Systems: Delayed-Release Systems
60
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
60
01:26Oral Drug Delivery Systems: Continuous-Release Systems
69
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
69
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
51
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
51
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
50
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
50